Roche, Genentech place a $100M bet on fibrosis, nabbing PhII program from Kiniksa

As parent company Roche aims to secure a place in the allogeneic CAR-T therapy race, Genentech is spinning its own deal to jump into fibrosis with a program from Kiniksa.

Genentech shelled out $80 million in upfront cash and another $20 million in near-term payments to license Kiniksa’s vixarelimab, formerly...

Click to view original post